JP2022500461A5 - - Google Patents

Info

Publication number
JP2022500461A5
JP2022500461A5 JP2021514550A JP2021514550A JP2022500461A5 JP 2022500461 A5 JP2022500461 A5 JP 2022500461A5 JP 2021514550 A JP2021514550 A JP 2021514550A JP 2021514550 A JP2021514550 A JP 2021514550A JP 2022500461 A5 JP2022500461 A5 JP 2022500461A5
Authority
JP
Japan
Prior art keywords
corneal region
patient
composition according
dryness
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021514550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500461A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/075406 external-priority patent/WO2020058504A1/en
Publication of JP2022500461A publication Critical patent/JP2022500461A/ja
Publication of JP2022500461A5 publication Critical patent/JP2022500461A5/ja
Pending legal-status Critical Current

Links

JP2021514550A 2018-09-22 2019-09-20 眼表面の損傷および乾燥の症状の治療のための眼科用組成物 Pending JP2022500461A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18196126 2018-09-22
EP18196126.9 2018-09-22
EP18198440.2 2018-10-03
EP18198440 2018-10-03
EP18202041 2018-10-23
EP18202041.2 2018-10-23
PCT/EP2019/075406 WO2020058504A1 (en) 2018-09-22 2019-09-20 Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness

Publications (2)

Publication Number Publication Date
JP2022500461A JP2022500461A (ja) 2022-01-04
JP2022500461A5 true JP2022500461A5 (cg-RX-API-DMAC7.html) 2022-09-27

Family

ID=68240699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514550A Pending JP2022500461A (ja) 2018-09-22 2019-09-20 眼表面の損傷および乾燥の症状の治療のための眼科用組成物

Country Status (11)

Country Link
US (2) US20210346313A1 (cg-RX-API-DMAC7.html)
EP (1) EP3852734A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022500461A (cg-RX-API-DMAC7.html)
KR (1) KR20210080388A (cg-RX-API-DMAC7.html)
CN (1) CN112739335A (cg-RX-API-DMAC7.html)
AU (2) AU2019342426A1 (cg-RX-API-DMAC7.html)
CA (1) CA3111873A1 (cg-RX-API-DMAC7.html)
IL (1) IL281516A (cg-RX-API-DMAC7.html)
PH (1) PH12021550621A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102818YA (cg-RX-API-DMAC7.html)
WO (1) WO2020058504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
WO2003088906A2 (en) * 2002-04-16 2003-10-30 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2895144B1 (en) * 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) * 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
EP3187168B1 (en) * 2014-10-09 2020-03-18 Mediproduce Inc. Eyelash cleaning agent
US20170087100A1 (en) * 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
KR102614858B1 (ko) * 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
CN111182893A (zh) * 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物

Similar Documents

Publication Publication Date Title
JP2022502421A5 (cg-RX-API-DMAC7.html)
Murray et al. The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis
Nijm et al. Understanding the dual dilemma of dry eye and glaucoma: an international review
Pasadhika et al. Ocular sarcoidosis
JP2024116245A5 (cg-RX-API-DMAC7.html)
Jaenen et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications
Park et al. Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial
Yang et al. A clinical study of the efficacy of topical corticosteroids on dry eye
Federici The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease
JP2015509500A5 (cg-RX-API-DMAC7.html)
US11865123B2 (en) Methods of inhibiting pathological angiogenesis
CA3072673A1 (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
KR20210080388A (ko) 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물
Lazreg et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
AU2020290443A1 (en) Carabachol-bromonidine formulation to enhance anti-presbyopia effects
Voss et al. Non-infectious and non-hereditary diseases of the corneal epithelium
US20230338307A1 (en) Prophylactic agent, ameliorating agent, and therapeutic agent for dry eye
Hashemian et al. Ocular presentations of amyloidosis
Qian et al. Efficacy of 0.05% cyclosporine A on tear inflammatory cytokines and goblet cell function after corneal refractive surgery
Bruce et al. Anterior eye disease and therapeutics AZ
El Fekih et al. Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA)
US20240216375A1 (en) Use of sympathetic activation inhibitor and/or alpha 1-adrenergic receptor inhibitor in preparing medicine for treating dry eyes
CN114040783A (zh) 可用于治疗干眼症的组合物和方法
RU2021107208A (ru) Офтальмологические композиции для лечения повреждения поверхности глаза и симптомов сухости глаз
JP5605072B2 (ja) 角結膜疾患の予防又は治療剤